New molecular mechanisms of duodenal ulceration

Annals of the New York Academy of Sciences

Volumn 1113, Issue , 2007, Pages 238-255

  Szabo, Sandor ^a,b   Deng, Xiaoming ^a   Khomenko, Tetyana ^a   Chen, Longchuan ^a   Tolstanova, Ganna ^a   Osapay, Klara ^a   Sandor, Zsuzsanna ^a   Xiong, Ximing ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Angiogenesis; Duodenal ulceration; Early growth response 1; Endostatin angiostatin; Endothelin 1; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC PROTEIN; ANGIOSTATIN; BINDING PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR A BINDING PROTEIN 1; EARLY GROWTH RESPONSE FACTOR A BINDING PROTEIN 2; ENDOSTATIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; FIBROBLAST GROWTH FACTOR 1; HYDROCHLORIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MERCAPTAMINE; PLATELET DERIVED GROWTH FACTOR; PROTEINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

BLOOD VESSEL INJURY; CELL DAMAGE; CONFERENCE PAPER; DUODENUM ULCER; ENDOTHELIUM CELL; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; ISCHEMIA; MICROVASCULATURE; MUCOSAL NECROSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; ULCER HEALING; UPREGULATION; WOUND HEALING IMPAIRMENT;

RATTUS; RODENTIA;

EID: 35548966680     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1391.033     Document Type: Conference Paper

References (78)

1. HUNT, R.H. 1990. Peptic ulcer disease. Gastroenterol. Clin. N. Am. 19: 1-225.
2. SONNENBERG, A. & J.E EVERHART. 1997. Health impact of peptic ulcer in the United States. Am. J. Gastroenterol. 92: 614-620.
3. LEVIN, T.R., J.A. SCHMITTDIEL, J.M. HENNING, et al. 1998. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am. J. Gastroenterol. 93: 743-747.
4. MARSHALL, B.J. &, H.M. WINDSOR. 2005. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med. Clin. North Am. 89: 313-344.
5. SELYE, H. 1950. Stress. The press, Acta Medica Publishers, Montreal.
6. ROBERT, A. & S. SZABO. 1983. Stress ulcers. In Selye's Guide to Stress Research. H. Selye, Ed.: Volume 3. The press, Van Nostrand Reinhold Publishing, New York, NY.
7. SZABO, S., W.F. SPILL & K.D. RAINSFORD. 1989. Non-steroidal anti-inflammatory drug-induced gastropathy: mechanisms and management. Med. Toxicol. Adv. Drug Exp. 4: 77-94.
8. SZABO, S. & H. SELYE. 1972. Duodenal ulcers produced by propionitrile in rats. Arch. Pathol. 93: 390-391.
9. SELYE, H. & S. SZABO. 1973. Experimental model for production of perforating duodenal ulcers by cysteamine in the rat. Nature 244: 458-459.
10. POULSEN, S.S. & S. SZABO. 1977. Mucosal surface morphology and histologic changes in the duodenum of the rat following administration of cysteamine. Br. J. Exp. Pathol. 58: 1-8.
11. SZABO, S., E.S. REYNOLDS & S.H. UNGER. 1982. Structure-activity relations between alkyl nucleophilic chemicals causing duodenal ulcer and adrenocortical necrosis. J. Pharmacol. Exp. Ther. 223: 68-76.
12. GIAMPAOLO, C., A.T. GRAY, R.A. OLSHEN & S. SZABO. 1991. Predicting chemically induced duodenal ulcer and adrenal necrosis with classification trees. Proc. Natl. Acad. Sci. USA 88: 6298-6302.
13. ADLER, R.S., G.T. GALLAGHER & S. SZABO. 1983. Duodenal ulcerogens cysteamine and propionitrile decrease duodenal neutralization of acid in the rat. Dig. Dis. Sci. 28: 716-723.
14. KIRKEGAARD, P., S.S. POULSEN, F.B. LOUD, et al. 1980. Cysteamine-induced duodenal ulcer and acid secretion in the rat. Scand. J. Gastroenterol. 15: 621-624.
15. SZABO, S., T. KHOMENKO, Z. GOMBOS, et al. 2000. Transcription factors and growth factors in ulcer healing. Aliment. Pharmacol. Ther. Suppl. 1: 33-43.
16. SZABO, S. & Z. SANDOR. 1996. Basic fibroblast growth factor and PDGF and GI diseases. Bailliere's Clin. Gastroenterol. 11: 922-927.
17. SZABO, S., A. VINCZE, Z. SANDOR, et al. 1998.Vascular approach to gastroduodenal ulceration: new studies with endothelins and VEGF. Dig. Dis. Sci. 43(Suppl): 40S-45S.
18. SZABO, S., X. DENG, T. KHOMENKO, et al. 2001. Gene expression and gene therapy in experimental duodenal ulceration. J. Physiol. Paris 95: 325-335.
19. DENG, X., S. SZABO, T. KHOMENKO, et al. 2004. Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats. J. Pharmacol. Exp. Ther. 311: 982-988.
20. YANAGISAWA, M., H. KURIHARA, S. KIMURA, et al. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 322: 411-415.
21. MACCUMBER, M.W., C.A. ROSS & S.H. SNYDER. 1990. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc. Natl. Acad. Sci. USA 87: 2359-2363.
22. MORALES, R.E., B.R. JOHNSON & S. SZABO. 1992. Endothelin induces vascular and mucosal lesions, enhances the injury by HCl/ethanol, and the antibody exerts gastroprotection. FASEB J. 6: 2354-2360.
23. DENG, X.M., S. SZABO, T. KHOMENKO, et al. 2007. Detection of duodenal ulcer-associated genes in rats. Dig. Dis. Sci. Accepted.
24. MATSUMARU, K., H. KASHIMURA, M. HASSAN, et al. 1997. A novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions induced by indomethacin and HCl in rat: role of endothelin-1. J. Gastroenterol. 32: 164-170.
25. MICHIDA, T., S. KAWANO, E. MASUDA, et al. 1994. Role of endothelin 1 in hemorrhagic shock-induced gastric mucosal injury in rats. Gastroenterology 106: 988-993.
26. MASUDA, E., S. KAWANO, T. MICHIDA, et al. 1997. Plasma and gastric mucosal endothelin-1 concentration in patients with peptic ulcer. Dig. Dis. Sci. 42: 314-318.
27. SHIGEMATSU, T., S. MIURA, M. HIROKAWA, et al. 1998. Induction of endothelin-1 synthesis by IL-1 and its modulation of rat intestinal cell growth. Am. J. Physiol. 38: G556-G563.
28. SEMENZA, G.L. 2000. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl. Physiol. 88: 1474-1480.
29. KOTCH, L.E., N.V. IYER, E. LAUGHNER & G.L. SEMENZA. 1999. Defective vascularization of HIF-1a-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev. Biol. 209: 254-267.
30. CATTARUZZA, M., C. DIMIGEN, H. EHRENREICH & M. HECKER. 2000. Stretch-induced endothelin B receptor-mediated apoptosis in vascular smooth muscle cells. FASEB J. 14: 991-998.
31. NAKAHASHI, T., K. FUKUO, H. NISHIMAKI, et al. 1998. Endothelin-l enhances nitric oxide-induced cell death in cultured vascular smooth-muscle cells. J. Cardiovasc. Phamacol. 31: S351-S353.
32. YAN, S.F., J.L. LU, Y.S. ZOU, et al. 1999. Hypoxia-associated induction of early response-1 gene expression. J. Biol. Chem. 274: 15030-15040.
33. SHUBEITA, H.E., P.M. MCDONOUGH, A.N. HARRIS, et al. 1990. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly and cardiac gene expression in ventricular myocytes. J. Biol. Chem. 265: 20555-20562.
34. NEYSES, L., J. NOUSKAS & H. VETTER. 1991. Inhibition of endothelin-l induced myocardial protein synthesis by an antisense oligonucleotide against the early growth response gene1. Biochem. Biophys. Res. Comm. 181: 22-27.
35. MAAS, A., C. GROHE, C. KUBISCH, et al. 1995. Hormonal induction of an immediate-early gene response in myogenic cell lines - a paradigm for heart growth. Eur. Heart J. 16(Suppl.C): 12-14.
36. BRUNEAU, B.G., L.A. PIAZZA & A.J. DE BOLD. 1997. BVP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am. J. Physiol. 273: H2678-H2686.
37. HOFER, G., C. GRIMMER, V.P. SUKHATME, et al. 1996. Transcription factor Egr-1 regulates glomerular mesangial cell proliferation. J. Biol. Chem. 271: 28306-28310.
38. BIESIADA, E., M. RAZANDI & E.R. LEVIN. 1996. Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. J. Biol. Chem. 271: 18576-18581.
39. SANTIAGO, F.S., H.C. LOWE, F.L. DAY, et al. 1999. Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am. J. Pathol. 154: 937-944.
40. QU, Z., L.A. WOLFRAIM, J. SVAREN, et al. 1998. The transcriptional corepressor NAB2 inhibits NGF-induced differentiation of PC12 cells. J. Cell Biol. 142: 1075-1082.
41. SILVERMAN, E.S., L.M. KHACHIGIAN, F.S SANTIAGO, et al. 1999. Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury. Am. J. Pathol. 155: 1311-1317.
42. QU, Z., L.A. WOLFRAIM, J. SVAREN, et al. 1998. The transcriptional corepressor NAB2 inhibits NGF-induced differentiation of PC12 cells. J. Cell Biol. 142: 1075-1082.
43. LUCERNA, M., D. MECHTCHERIAKOVA, A. KADL, et al. 2003. NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells. J. Biol. Chem. 278: 11433-11440.
44. KHACHIGIAN, L.M., A.J. WILLIAMS & T. COLLINS. 1995. Interplay of Sp1 and Egr-1 on the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. J. Biol. Chem. 270: 27679-27686.
45. KHACHIGIAN, L.M., V. LINDNER, A.J. WILLIAMS & T. COLLINS. 1996. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 271: 1427-1431.
46. VIDAL, F., J. ARAGONES, A. ARANTZAZU & M.O. DE LANDAZURI. 2000. Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. Blood 95: 3387-3394.
47. VINCZE, A., M. NAGATA, Z. SANDOR & S. SZABO. 1996. ELISA and Western blot studies with basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) in experimental duodenal ulcer development and healing. Inflammopharmacology 4: 261-265.
48. FOLKMAN, J., S. SZABO, M. STOVROFF, et al. 1991. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann. Surg. 241: 414-425.
49. SZABO, S. et al. 1995. Growth factors: "New endogenous drugs" for ulcer healing. Scand. J. Gastroenterol. 30(Suppl. 210): 15-18.
50. SZABO, S. et al. 2001. Angiogenesis and growth factors in ulcer healing. In New Angiogenesis. D. Fan Tai-Ping and E.C. Kohn, Eds.: 119-211. Totowa. Humana Press, NJ.
51. DENG, X.M. et al. 2006. Increased expression of both angiogenic VEGF, and anti-angiogenic endostatin and angiostatin in ulcerative colitis in rats, mice and humans: an explanation for impaired and delayed healing. Gastroenterology 128: A998.
52. SANDOR, ZS., X.M. DENG, T. KHOMENKO, et al. 2006. Altered angiogenic balance in ulcerative colitis: A key to impaired healing? Biochem. Biophys. Res. Commun. 350: 147-150.
53. HANAHAN, D. & J. FOLKMAN. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
54. FOLKMAN, J. 2006. Angiogenesis. Annu. Rev. Med. 57: 1-18.
55. PANDYA, N.M., N.S. DHALLA & D.D. SANTANI. 2006. Angiogenesis - a new target for future therapy. Vascul. Pharmacol. 44: 265-274.
56. O'REILLY, M.S. et al. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
57. O'REILLY, M.S. et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
58. CLAESSON-WELSH, L et al. 1998. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA 95: 5579-5583.
59. TADDEI, L. et al. 1999. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem. Biophys. Res. Commun. 263: 340-345.
60. MOTT, J.D. & Z. WERB. 2004. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16: 558-564.
61. SOTTILE, J. 2004. Regulation of angiogenesis by extracellular matrix. Biochem. Biophys. Acta 1654: 13-22.
62. CORNELIUS, L.A. et al. 1998. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161: 6845-6852.
63. FERRERAS, M., U. FELBOR, T. LENHARD, et al. 2000. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 86: 247-251.
64. NILSSON, U.W. & C. DABROSIN. 2006. Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res. 66: 4789-4704.
65. SZABO, S., TOLSTANOVA, G., DENG, X.M., et al. 2007. New molecular mechanisms of GI inflammation and neoplasia [abstract]. The 12th Taishotoyama International Symposium on Gastroenterology, Shimoda, Japan, 12.
66. SZABO, S. 2007. New molecular mechanisms of duodenal ulcer - The most frequent "peptic ulcer" [abstract]. Hans Selye Centennial Symposium, Quebec, Canada, 28.
67. SMITH, E. & R. HOFFMAN. 2005. Multiple fragments related to angiostatin and endostatin in fluid from venous leg ulcers. Wound Rep. Reg. 13: 148-157.
68. BUCALO, B., W.H. EAGLSTEIN & V. FALANGA. 1993. Inhibition of cell proliferation by chronic wound fluid. Wound Rep. Reg. 1: 181-186.
69. DRINKWATER, S.L., S. SMITH, B.M. SAWYER & K.G. BURNAND. 2002. Effect of venous ulcer exudates on angiogenesis in vitro. Br. J. Surg. 89: 709-713.
70. DRINKWATER, S.L., K.G BURNAND, R. DING & A. SMITH. 2003. Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J. Vasc. Surg. 38: 1106-1112.
71. KATO, M. et al. 1998. Physiological degradation converts the soluble syndecanl ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 4: 691-697.
72. GRINNELL, F. & M. ZHU. 1996. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alphal-proteinase inhibitor, and alpha2-macroglobulin. J. Invest. Dermatol. 106: 335-341.
73. WECKROTH, M., A. VAHERI, J. LAUHARANTA, et al. 1996. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J. Invest. Dermatol. 106: 1119-1124.
74. LAUER, G. et al. 2000. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J. Invest. Dermatol. 115: 12-18.
75. BOEHM, T., J. FOLKMAN, T. BROWDER & M.S. O'REILLY. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407.
76. YAMAGUCHI, N. et al. 1999. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18: 4414-4423.
77. MACDONALD, N.J. et al. 2001. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J. Biol. Chem. 276: 25190-25196.
78. BLOCH, W. et al. 2000. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 14: 2373-2376.